Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients
Canadian Hematology Today · 2022
DOI: 10.58931/cht.2022.1s1029 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2022. Verfasst von Ronan Foley und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Approximately 40% of Diffuse large B cell lymphoma (DLBCL) patients relapse or do not respond to first line therapy. Deciding whether to pursue intensive therapies in these patients is complex, given the limited therapeutic access landscape for R/R DLCBL patients, as well as the risk of serious adverse events. Emerging therapies open up new possibilities.
Zitieren
APA
Foley, R., Owen, C., Tabchi, S., & Razavi, G. (2022). Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. Canadian Hematology Today. https://doi.org/10.58931/cht.2022.1s1029
Vancouver
Foley R, Owen C, Tabchi S, Razavi G. Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. Canadian Hematology Today. 2022. doi:10.58931/cht.2022.1s1029
BibTeX
@article{Foley2022,
author = {Foley, Ronan and Owen, Carolyn and Tabchi, Samer and Razavi, Ghazaleh},
title = {Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients},
journal = {Canadian Hematology Today},
year = {2022},
doi = {10.58931/cht.2022.1s1029}
}
EUVIMED